Abstract 1502P
Background
Rectal cancer treatments have improved significantly over the past two decades, leading to higher survival rates. However, there's a growing emphasis on the long-term quality of life for survivors, including addressing sexual health needs. Our study aims to evaluate QOL, particularly sexual dysfunction, using validated tools like EORTC QLQ-C30, QLQ-CR29, and GRISS, aiming to improve care for rectal cancer patients.
Methods
Validated questionnaires (EORTC QLQ-C30, QLQ-CR29, GRISS) were completed by participants, assessing various aspects of quality of life and sexual satisfaction. Statistical analyses included tests for normality, descriptive analyses of patient characteristics, correlation analyses between questionnaire scores, and comparison of median scores using appropriate tests.
Results
The study included a total of 83 participants. Mean age of 55.95 ± 11.53, predominantly under 65 years (79.5%). A majority of patients (65.1%) had a stoma, and 78.3% underwent surgery, with 67.5% retaining sphincter function. The cohort was divided into non-metastatic (60.2%) and metastatic (39.8%) groups Significant correlations were observed between the Golombok Total Score and various subscores of the C30 scale. The fatigue subscore correlated positively with Golombok-female Total Score (r=0.331, p=0.041) and Golombok-male Total Score (r=0.370, p=0.042). Body image (p
Conclusions
This study demonstrates the profound and varied impact of rectal cancer treatment on patients' sexual health and overall quality of life, particularly affected by the presence of a stoma and metastatic disease.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1607P - Association of the lipid biomarker, PCPro, and clinical outcomes in the ENZAMET trial (ANZUP 1304)
Presenter: Lisa Horvath
Session: Poster session 10
1608P - Prostate cancer working group 4 (PCWG4) preliminary criteria using serial PSMA PET/CT for response evaluation: Analysis from the PRINCE trial
Presenter: Michael Hofman
Session: Poster session 10
1609P - PSMA-PET and PROMISE re-define stage and risk in patients with prostate cancer
Presenter: Wolfgang Fendler
Session: Poster session 10
1610P - Circulating tumour cell (CTC) enumeration and overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with xaluritamig
Presenter: Andrew Armstrong
Session: Poster session 10
1611P - Haematologic impact of [177Lu]Lu-PSMA-617 versus ARPI change in patients with metastatic castration-resistant prostate cancer in PSMAfore
Presenter: Kim Nguyen Chi
Session: Poster session 10
1612P - Impact of FANCA, ATM, CDK12 alterations on survival in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: David Lorente
Session: Poster session 10
1613P - Clinically advanced prostate cancer (CAPC) featuring BRCA2 loss: A comprehensive genomic profiling (CGP) study
Presenter: Chiara Mercinelli
Session: Poster session 10
1614P - PSA responses and PSMA scan changes after immunotherapy for biochemically recurrent prostate cancer (BCR) without androgen deprivation therapy (ADT)
Presenter: Ravi Madan
Session: Poster session 10
1615P - A new prognostic model of overall survival (OS) in patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC)
Presenter: Susan Halabi
Session: Poster session 10